{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T02:02:34Z","timestamp":1784080954846,"version":"3.55.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>While the use of testosterone replacement therapy (TRT) in men undergoing active surveillance (AS) for prostate cancer (PCa) has been historically contraindicated, recent studies have contributed to a paradigm shift to this approach.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To examine the impact of testosterone on prostate-specific antigen (PSA) levels and prostate biopsy progression in men with low testosterone on AS for PCa.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective single-center analysis was conducted on men undergoing AS for PCa who subsequently underwent TRT. Men previously treated for PCa were excluded. PSA and testosterone levels were recorded at regular intervals one year before and after the initiation of testosterone. ANOVA was used to analyze variance in PSA and testosterone levels, and paired t-tests and linear regression analysis were performed. Baseline and surveillance biopsies were documented.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>The primary outcomes were changes in PSA levels and biopsy progression following initiation of testosterone therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Forty-three men met the inclusion criteria. Median (IQR) testosterone level before testosterone therapy was 272 (221.5\u2013333.5) ng\/dL and 578.5 (354.5\u2013846.5) ng\/dL after therapy (P\u2009&amp;lt;\u20090.01). No significant variation in mean PSA levels was observed (P\u2009=\u20090.87). Baseline biopsies were available for 27 patients, showing Gleason 3\u2009+\u20093\u2009=\u20096 in no more than three cores. Fifteen (55.6%) patients had one or more surveillance biopsies after starting testosterone therapy. Of these, 12 (80.0%) had no disease progression in biopsies over a mean of 44.3\u00a0months on testosterone. Three patients (20.0%) had a Gleason score 7 on biopsy after a mean of 79.5\u00a0months on testosterone therapy. No patients developed metastatic disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>Testosterone therapy did not result in statistically significant changes in PSA levels in men with low testosterone on AS. Pathology changes were inconclusive, but the available data showed no apparent increase in PCa progression or disease worsening in the cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths and Limitations<\/jats:title>\n                  <jats:p>The study\u2019s strengths include a longitudinal follow-up design and use of multiple statistical analyses. Limitations include the retrospective design, small sample size which may limit generalizability, and lack of control group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>No significant change in PSA level was observed after initiating testosterone therapy, despite an increase in testosterone levels. Despite limited biopsy data, our findings suggest similar rates of disease progression compared to the general AS population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdaf003","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T07:13:46Z","timestamp":1738566826000},"page":"432-438","source":"Crossref","is-referenced-by-count":5,"title":["Testosterone replacement therapy in men on active surveillance for prostate cancer"],"prefix":"10.1093","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4583-891X","authenticated-orcid":false,"given":"James","family":"Applewhite","sequence":"first","affiliation":[{"name":"Baylor College of Medicine , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"McCarter","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3053-5828","authenticated-orcid":false,"given":"Gal","family":"Saffati","sequence":"additional","affiliation":[{"name":"Scott Department of Urology, Baylor College of Medicine , Houston, TX 77005,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0757-451X","authenticated-orcid":false,"given":"Shane","family":"Kronstedt","sequence":"additional","affiliation":[{"name":"Scott Department of Urology, Baylor College of Medicine , Houston, TX 77005,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hinojosa-Gonzalez","sequence":"additional","affiliation":[{"name":"Scott Department of Urology, Baylor College of Medicine , Houston, TX 77005,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"La","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rioke M","family":"Diejomaoh","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine , Houston, TX 77030,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry I","family":"Lipshultz","sequence":"additional","affiliation":[{"name":"Scott Department of Urology, Baylor College of Medicine , Houston, TX 77005,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Khera","sequence":"additional","affiliation":[{"name":"Scott Department of Urology, Baylor College of Medicine , Houston, TX 77005,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"issue":"3","key":"2025041108412021900_ref1","doi-asserted-by":"publisher","first-page":"e231439","DOI":"10.1001\/jamanetworkopen.2023.1439","article-title":"Time trends and variation in the use of active surveillance for management of low-risk prostate Cancer in the US","volume":"6","author":"Cooperberg","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2025041108412021900_ref2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"issue":"3","key":"2025041108412021900_ref3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1113162","article-title":"Radical prostatectomy versus observation for localized prostate cancer","volume":"367","author":"Wilt","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"2025041108412021900_ref4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.euo.2018.03.015","article-title":"Active surveillance for prostate cancer in a real-life cohort: comparing outcomes for PRIAS-eligible and PRIAS-ineligible patients","volume":"1","author":"Soeterik","year":"2018","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"2025041108412021900_ref5","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1210\/jcem.86.2.7219","article-title":"Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging","volume":"86","author":"Harman","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025041108412021900_ref6","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/j.1742-1241.2006.00992.x","article-title":"Prevalence of hypogonadism in males aged at least 45 years: the HIM study","volume":"60","author":"Mulligan","year":"2006","journal-title":"Int J Clin Pract"},{"issue":"5","key":"2025041108412021900_ref7","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1210\/jc.2003-032006","article-title":"Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men","volume":"89","author":"Wang","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025041108412021900_ref8","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1111\/jsm.12429","article-title":"Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends","volume":"11","author":"Kaplan","year":"2014","journal-title":"J Sex Med"},{"key":"2025041108412021900_ref9","first-page":"293","article-title":"Studies on prostatic cancer I. The effect of castration, of estrogen and of androgen injection on serum phosphtases in metastatic carcinoma of the prostate","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res"},{"issue":"5","key":"2025041108412021900_ref10","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.eururo.2006.06.034","article-title":"Testosterone and prostate cancer: an historical perspective on a modern myth","volume":"50","author":"Morgentaler","year":"2006","journal-title":"Eur Urol"},{"issue":"12","key":"2025041108412021900_ref11","doi-asserted-by":"publisher","first-page":"819","DOI":"10.4111\/kju.2010.51.12.819","article-title":"Is a decreased serum testosterone level a risk factor for prostate cancer? A cohort study of korean men","volume":"51","author":"Shin","year":"2010","journal-title":"Korean J Urol"},{"issue":"6","key":"2025041108412021900_ref12","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.urology.2006.08.1058","article-title":"Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng\/ml or less","volume":"68","author":"Morgentaler","year":"2006","journal-title":"Urology"},{"issue":"4","key":"2025041108412021900_ref13","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.juro.2010.11.084","article-title":"Testosterone therapy in men with untreated prostate cancer","volume":"185","author":"Morgentaler","year":"2011","journal-title":"J Urol"},{"issue":"1","key":"2025041108412021900_ref14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4103\/1008-682X.160270","article-title":"Can testosterone therapy be offered to men on active surveillance for prostate cancer?","volume":"18","author":"Kacker","year":"2016","journal-title":"Preliminary results Asian J Androl"},{"issue":"10","key":"2025041108412021900_ref15","doi-asserted-by":"publisher","first-page":"429.e1","DOI":"10.1016\/j.urolonc.2023.06.002","article-title":"Does testosterone replacement therapy increase the risk of conversion to treatment in patients with prostate cancer on active surveillance?","volume":"41","author":"Daza","year":"2023","journal-title":"Urol Oncol"},{"issue":"10","key":"2025041108412021900_ref16","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1111\/j.1464-410X.2009.08980.x","article-title":"Testosterone replacement in prostate cancer survivors with hypogonadal symptoms","volume":"105","author":"Leibowitz","year":"2010","journal-title":"BJU Int"},{"issue":"12","key":"2025041108412021900_ref17","doi-asserted-by":"publisher","first-page":"530.e9","DOI":"10.1016\/j.urolonc.2016.07.004","article-title":"Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer","volume":"34","author":"Hashimoto","year":"2016","journal-title":"Urol Oncol"},{"issue":"8","key":"2025041108412021900_ref18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.urolonc.2020.04.008","article-title":"Testosterone replacement therapy (TRT) and prostate cancer: an updated systematic review with a focus on previous or active localized prostate cancer","volume":"38","author":"Lenfant","year":"2020","journal-title":"Urol Oncol"},{"issue":"4","key":"2025041108412021900_ref19","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1097\/JU.0000000000000031","article-title":"Active surveillance of prostate cancer is a viable option for men younger than 60 years","volume":"201","author":"Salari","year":"2019","journal-title":"J Urol"},{"issue":"2","key":"2025041108412021900_ref20","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/j.1743-6109.2008.01066.x","article-title":"Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer","volume":"6","author":"Morgentaler","year":"2009","journal-title":"J Sex Med"},{"issue":"4","key":"2025041108412021900_ref21","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.juro.2016.04.069","article-title":"Testosterone therapy in patients with treated and untreated prostate cancer: impact on oncologic outcomes","volume":"196","author":"Ory","year":"2016","journal-title":"J Urol"},{"key":"2025041108412021900_ref22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.euros.2024.01.005","article-title":"Oncologic outcomes of testosterone therapy for men on active surveillance for prostate cancer: a population-based analysis","volume":"60","author":"Kaplan-Marans","year":"2024","journal-title":"Eur Urol Open Sci"},{"issue":"10","key":"2025041108412021900_ref23","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1111\/jsm.12266","article-title":"Serum PSA as a predictor of testosterone deficiency","volume":"10","author":"Rastrelli","year":"2013","journal-title":"J Sex Med"},{"issue":"11","key":"2025041108412021900_ref24","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1111\/jsm.12657","article-title":"Factors influencing prostate-specific antigen response among men treated with testosterone therapy for 6 months","volume":"11","author":"Morgentaler","year":"2014","journal-title":"J Sex Med"},{"issue":"3","key":"2025041108412021900_ref25","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.juro.2011.04.065","article-title":"Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory","volume":"186","author":"Khera","year":"2011","journal-title":"J Urol"},{"issue":"5","key":"2025041108412021900_ref26","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.eururo.2012.05.025","article-title":"Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the reduction by Dutasteride of prostate cancer events trial","volume":"62","author":"Muller","year":"2012","journal-title":"Eur Urol"},{"issue":"2","key":"2025041108412021900_ref27","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/pcan.2013.60","article-title":"The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis","volume":"17","author":"Cui","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"15","key":"2025041108412021900_ref28","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1001\/jamainternmed.2013.6895","article-title":"Trends in androgen prescribing in the United States, 2001 to 2011","volume":"173","author":"Baillargeon","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"2","key":"2025041108412021900_ref29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa2215025","article-title":"Cardiovascular safety of testosterone-replacement therapy","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"2025041108412021900_ref30","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/JU.0000000000003855","article-title":"Update to the testosterone guideline","volume":"211","author":"Trost","year":"2024","journal-title":"J Urol"},{"issue":"2","key":"2025041108412021900_ref31","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.juro.2018.03.115","article-title":"Evaluation and Management of Testosterone Deficiency: AUA guideline","volume":"200","author":"Mulhall","year":"2018","journal-title":"J Urol"},{"key":"2025041108412021900_ref32","volume-title":"Prostate Cancer","author":"Giona","year":"2021"},{"issue":"5B","key":"2025041108412021900_ref33","first-page":"3007","article-title":"Occult prostate cancer effects the results of case-control studies due to verification bias","volume":"28","author":"Iguchi","year":"2008","journal-title":"Anticancer Res"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/22\/3\/432\/61738088\/qdaf003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/22\/3\/432\/61738088\/qdaf003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T08:41:29Z","timestamp":1744360889000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/22\/3\/432\/7996986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2,3]]},"published-print":{"date-parts":[[2025,4,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdaf003","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,2,3]]}}}